Decision to start first-line (1L) treatment with TDC according to the current SmPCs
Histologically or cytologically confirmed diagnosis of NSQ mNSCLC (incl. LCNEC if considered NSCLC-like by the treating physician)
No sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) alterations
Molecular Next Generation Sequencing (NGS) panel as per institutional standard has been initiated (including the following genes: KRAS, STK11, KEAP1, and TP53)
TTF-1 expression analysis has been initiated
PD-L1 expression analysis has been initiated
Women of childbearing potential must use effective contraception during treatment with durvalumab and for at least 3 months after the last dose of durvalumab
Ability to understand the study concept
Provision of signed informed consent form in accordance with applicable local provisions
You may not be if
Current participation in interventional clinical trials
Contraindications according to current SmPCs
Any active tumor other than metastatic NSCLC\*
Mixed histology NSCLC with both adenocarcinoma and squamous cell carcinoma components (adenosquamous carcinoma or any mixed NSQ- squamous tumor), regardless of the predominant component
* determined by investigator as likely to influence the prognosis or management of mNSCLC
Clareo Health | NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations
